Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Biosite Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Biosite Diagnostics: Triage point-of-care panel for CK-MB, myoglobin and troponin I measurement gains 510(k) clearance to be used in conjunction with the Triage meter for myocardial infarction detection. Biosite awaits pending 510(k) clearances for test quality control/calibration and Triage meter products before launching the Triage panel. The 15-minute test consists of a small, single-use cartridge utilizing capillary technology to control blood flow through zones containing immobilized antibodies to the three biochemical markers, which are quantitatively measured by the Triage Meter. Data from a four-center, 800-patient study show "sensitivity and specificity of the Triage cardiac panel was substantially equivalent to commercially available analyzer-based assays," the firm claims...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT008976

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel